Abstract 1813
Background
Few studies have compared long-term patient reported AEs of men with Prostate Cancer (PCa) treated with dose-escalation by means of BT/RT to RT (70-78 Gy) alone. In this study, we compare AEs and quality of life (QoL) between these two treatment modalities.
Methods
259 eligible men from the BT/RT cohort (2004-2011) and 123 patients (2009-2010) from a RT cohort assessed their AEs and QoL by questionnaires a minimum of 5 years after treatment. Hormonal therapy was given for 1-2 years. EPIC-26 covered urinary, sexual and bowel function and bother. The hormone domain was excluded. The SF-12 questionnaire covered QoL. The scores ranged from 0 (worst) to 100 (best). Clinical significance was set to a score difference > 10 points. Statistical significance was evaluated by Student t-test with significance level p < 0.05. Chronic fatigue was reported as percentage.
Results
Median age at survey was 74 years for both cohorts. The EPIC-26 and SF12 scores for the above domains were similar in the two cohorts with no clinical or statistical significance (Table). Chronic fatigue was higher after treatment with RT compared BT/RT, although not significantly.Table: 853P
| Measure | BT/RT Mean (SD) | RT Mean (SD) | P value |
|---|---|---|---|
| Sexual function | 27.9 (29.5) n = 255 | 20.8 (24.3) n = 120 | 0.06 |
| Sexual bother | 48.2 (37.5) n = 254 | 45.9 (34.7) n = 121 | 0.56 |
| Urinary function | 83.6 (18.0) n = 258 | 80.1 (20.5) n = 123 | 0.10 |
| Urinary irritation/obstruction | 81.3 (19.6) n = 249 | 81.8 (16.8) n = 113 | 0.80 |
| Urinary incontinence | 88.7 (18.1) n = 258 | 85.0 (22.5) n = 123 | 0.11 |
| Urinary bother | 79.9 (26.5) n = 257 | 77.6 (30.0) n = 123 | 0.47 |
| Bowel function | 86.7 (20.6) n = 254 | 83.1 (21.7) n = 121 | 0.12 |
| Bowel bother | 83.0 (25.1) n = 258 | 80.4 (26.7) n = 121 | 0.34 |
| PCS12 (SF12) | 46.4 (10.5) n = 224 | 45.1 (10.1) n = 101 | 0.30 |
| MCS12 (SF12) | 53.6 (8.0) n = 224 | 52.7 (9.2) n = 101 | 0.38 |
| Chronic fatigue | 22.0% n = 199 | 27.1% n = 86 | 0.28 |
Conclusions
Dose-escalation by means of BT/RT does not increase the AEs reported for the urinary, bowel and sexual domains of EPIC-26 or health-related QoL. Hence, BT/RT is a good treatment option for eligible patients.
Clinical trial identification
Legal entity responsible for the study
Wolfgang Lilleby.
Funding
Raagholt Foundation, Bergersen Foundation, Eckbo Foundation.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract